JP2008513366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513366A5 JP2008513366A5 JP2007530802A JP2007530802A JP2008513366A5 JP 2008513366 A5 JP2008513366 A5 JP 2008513366A5 JP 2007530802 A JP2007530802 A JP 2007530802A JP 2007530802 A JP2007530802 A JP 2007530802A JP 2008513366 A5 JP2008513366 A5 JP 2008513366A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- protein kinase
- dependent
- cancer
- kinase dependent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 9
- 230000001419 dependent effect Effects 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 102000001253 Protein Kinase Human genes 0.000 claims 14
- 108060006633 protein kinase Proteins 0.000 claims 14
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 108091008606 PDGF receptors Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 201000009925 nephrosclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- JNLSTLQFDDAULK-UHFFFAOYSA-N 6-[6-(hydroxymethyl)pyrimidin-4-yl]oxy-n-[3-(trifluoromethyl)phenyl]naphthalene-1-carboxamide Chemical compound C1=NC(CO)=CC(OC=2C=C3C=CC=C(C3=CC=2)C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=N1 JNLSTLQFDDAULK-UHFFFAOYSA-N 0.000 claims 1
- 206010051113 Arterial restenosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PGFQDLOMDIBAPY-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C(F)C(C(F)(F)F)=C1 PGFQDLOMDIBAPY-UHFFFAOYSA-N 0.000 description 1
- DLOAPXKILLGWHB-UHFFFAOYSA-N 6-(6-acetamidopyrimidin-4-yl)oxy-n-[4-[(4-propan-2-ylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]isoquinoline-1-carboxamide Chemical compound C1CN(C(C)C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=NC=CC2=CC(OC=3N=CN=C(NC(C)=O)C=3)=CC=C12 DLOAPXKILLGWHB-UHFFFAOYSA-N 0.000 description 1
- UQALKJYOYJHRRA-UHFFFAOYSA-N 6-(6-chloropyrimidin-4-yl)oxy-n-[4-fluoro-3-(trifluoromethyl)phenyl]isoquinoline-1-carboxamide Chemical group C1=C(C(F)(F)F)C(F)=CC=C1NC(=O)C1=NC=CC2=CC(OC=3N=CN=C(Cl)C=3)=CC=C12 UQALKJYOYJHRRA-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- WEQFCSZFUXTHSP-UHFFFAOYSA-N CC(C)N1CCN(CC(C=C2)=C(C(F)(F)F)C=C2NC(C2=NC(OC3=NC=NC(Cl)=C3)=CC3=CC=CC=C23)=O)CC1 Chemical compound CC(C)N1CCN(CC(C=C2)=C(C(F)(F)F)C=C2NC(C2=NC(OC3=NC=NC(Cl)=C3)=CC3=CC=CC=C23)=O)CC1 WEQFCSZFUXTHSP-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0420520A GB0420520D0 (en) | 2004-09-15 | 2004-09-15 | Organic compounds |
| GB0420520.9 | 2004-09-15 | ||
| GB0511687.6 | 2005-06-08 | ||
| GB0511687A GB0511687D0 (en) | 2005-06-08 | 2005-06-08 | Organic compounds |
| PCT/IB2005/004030 WO2006059234A2 (en) | 2004-09-15 | 2005-09-14 | Bicyclic amides as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011050331A Division JP2011148808A (ja) | 2004-09-15 | 2011-03-08 | キナーゼ阻害剤としての二環式アミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008513366A JP2008513366A (ja) | 2008-05-01 |
| JP2008513366A5 true JP2008513366A5 (enExample) | 2011-04-28 |
| JP4950889B2 JP4950889B2 (ja) | 2012-06-13 |
Family
ID=35705284
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530802A Expired - Fee Related JP4950889B2 (ja) | 2004-09-15 | 2005-09-14 | キナーゼ阻害剤としての二環式アミド |
| JP2011050331A Pending JP2011148808A (ja) | 2004-09-15 | 2011-03-08 | キナーゼ阻害剤としての二環式アミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011050331A Pending JP2011148808A (ja) | 2004-09-15 | 2011-03-08 | キナーゼ阻害剤としての二環式アミド |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8026247B2 (enExample) |
| EP (1) | EP1794149A2 (enExample) |
| JP (2) | JP4950889B2 (enExample) |
| KR (3) | KR20100103890A (enExample) |
| CN (1) | CN101693709A (enExample) |
| AR (1) | AR050932A1 (enExample) |
| AU (2) | AU2005310968C1 (enExample) |
| BR (1) | BRPI0515446A (enExample) |
| CA (2) | CA2738383A1 (enExample) |
| EC (1) | ECSP077324A (enExample) |
| GT (1) | GT200500260A (enExample) |
| IL (1) | IL181720A0 (enExample) |
| MA (1) | MA28876B1 (enExample) |
| MX (1) | MX2007003013A (enExample) |
| MY (2) | MY148246A (enExample) |
| NO (1) | NO20071875L (enExample) |
| NZ (3) | NZ587806A (enExample) |
| PE (1) | PE20060664A1 (enExample) |
| RU (3) | RU2448103C2 (enExample) |
| SG (1) | SG155921A1 (enExample) |
| TN (1) | TNSN07093A1 (enExample) |
| TW (1) | TW200626576A (enExample) |
| WO (1) | WO2006059234A2 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1667964T1 (sl) | 2003-09-19 | 2009-12-31 | Janssen Pharmaceutica Nv | 4-((fenoksialkil)tio)-fenoksiocetne kisline in analogi |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| MY147518A (en) | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| ZA200804679B (en) | 2005-12-08 | 2010-02-24 | Millenium Pharmaceuticals Inc | Bicyclic compounds with kinase inhibitory activity |
| GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
| GB0605120D0 (en) * | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| EP2574340A3 (en) | 2006-04-07 | 2013-04-17 | Novartis AG | Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor |
| PE20080188A1 (es) | 2006-04-18 | 2008-03-10 | Janssen Pharmaceutica Nv | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol |
| WO2008031835A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
| PT2114900T (pt) | 2007-01-31 | 2019-01-17 | Ym Biosciences Australia Pty | Compostos à base de tiopirimidina e as suas utilizações |
| KR20100016584A (ko) * | 2007-04-17 | 2010-02-12 | 노파르티스 아게 | 암 치료제로서의 나프탈렌 카르복실산 아미드의 에테르 |
| KR20100017441A (ko) * | 2007-04-27 | 2010-02-16 | 아스트라제네카 아베 | 증식성 병태를 치료하기 위한 ＥｐｈＢ4 키나제 억제제로서의 Ｎ'-(페닐)-Ｎ-(모르폴린-4-일-피리딘-2-일)-피리미딘-2,4-디아민 유도체 |
| CL2008002786A1 (es) * | 2007-09-20 | 2009-05-15 | Novartis Ag | Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion. |
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| US20110112121A1 (en) | 2009-07-06 | 2011-05-12 | Joerg Berghausen | Pharmaceutical Compositions and Solid Forms |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| EA022873B1 (ru) | 2010-10-27 | 2016-03-31 | Новартис Аг | Применение ингибитора vegf-r2 для лечения офтальмологического сосудистого заболевания |
| GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| CA2824028A1 (en) | 2011-01-06 | 2012-07-12 | Beta Pharma Canada Inc. | Novel ureas for the treatment and prevention of cancer |
| SG191710A1 (en) | 2011-01-21 | 2013-08-30 | Eisai R&D Man Co Ltd | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| EP3064489A4 (en) * | 2013-11-01 | 2017-06-21 | Ube Industries, Ltd. | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| CN104860885B (zh) * | 2014-02-24 | 2017-11-17 | 中国科学院上海药物研究所 | 萘酰胺类化合物、其制备方法和用途 |
| EP3218380B1 (en) | 2014-11-16 | 2021-03-17 | Array Biopharma, Inc. | Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| WO2017003862A1 (en) * | 2015-07-01 | 2017-01-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| TN2019000332A1 (en) | 2016-04-04 | 2021-05-07 | Loxo Oncology Inc | Methods of treating pediatric cancers |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| IL304018A (en) | 2016-04-04 | 2023-08-01 | Loxo Oncology Inc | Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide |
| ES2952056T3 (es) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| JP7286755B2 (ja) | 2018-07-31 | 2023-06-05 | ロクソ オンコロジー， インコーポレイテッド | （ｓ）－５－アミノ－３－（４－（（５－フルオロ－２－メトキシベンズアミド）メチル）フェニル）－１－（１，１，１－トリフルオロプロパン－２－イル）－１ｈ－ピラゾール－４－カルボキサミドの噴霧乾燥分散体および製剤 |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| MX2022007171A (es) | 2019-12-27 | 2022-08-22 | Schroedinger Inc | Compuestos cíclicos y métodos de uso de estos. |
| TWI786742B (zh) * | 2020-07-23 | 2022-12-11 | 大陸商深圳晶泰科技有限公司 | 吡啶酮類化合物及其製備方法和應用 |
| CN116490507A (zh) | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| US20240148732A1 (en) | 2021-01-26 | 2024-05-09 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
| WO2026006488A1 (en) * | 2024-06-26 | 2026-01-02 | Antinous Technology Company Limited | Angiogenesis inhibitors and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| AU6998000A (en) * | 1999-08-27 | 2001-03-26 | Boehringer Ingelheim Pharma Kg | Substituted indolinones as tyrosine kinase inhibitors |
| MXPA02007957A (es) | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
| AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| ATE419239T1 (de) | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
| AR037647A1 (es) * | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| WO2004020434A1 (ja) | 2002-08-30 | 2004-03-11 | Eisai Co., Ltd. | 含窒素芳香環誘導体 |
| AR041992A1 (es) | 2002-11-06 | 2005-06-08 | Smithkline Beecham Corp | Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla |
| BRPI0414011A (pt) | 2003-08-29 | 2006-10-24 | Pfizer | naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos |
| EP1670787B1 (en) | 2003-09-11 | 2012-05-30 | iTherX Pharma, Inc. | Cytokine inhibitors |
| WO2005070891A2 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc | Compounds and methods of use |
| US7285545B2 (en) | 2004-05-03 | 2007-10-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| GB0421525D0 (en) * | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
-
2005
- 2005-09-12 PE PE2005001058A patent/PE20060664A1/es not_active Application Discontinuation
- 2005-09-13 AR ARP050103817A patent/AR050932A1/es not_active Application Discontinuation
- 2005-09-13 MY MYPI20092342A patent/MY148246A/en unknown
- 2005-09-13 MY MYPI20054290A patent/MY147640A/en unknown
- 2005-09-14 JP JP2007530802A patent/JP4950889B2/ja not_active Expired - Fee Related
- 2005-09-14 KR KR1020107020439A patent/KR20100103890A/ko not_active Abandoned
- 2005-09-14 CA CA2738383A patent/CA2738383A1/en not_active Abandoned
- 2005-09-14 NZ NZ587806A patent/NZ587806A/en not_active IP Right Cessation
- 2005-09-14 WO PCT/IB2005/004030 patent/WO2006059234A2/en not_active Ceased
- 2005-09-14 NZ NZ553094A patent/NZ553094A/en not_active IP Right Cessation
- 2005-09-14 SG SG200906116-9A patent/SG155921A1/en unknown
- 2005-09-14 BR BRPI0515446-4A patent/BRPI0515446A/pt not_active IP Right Cessation
- 2005-09-14 CA CA2574829A patent/CA2574829C/en not_active Expired - Fee Related
- 2005-09-14 CN CN200910205861A patent/CN101693709A/zh active Pending
- 2005-09-14 US US11/575,025 patent/US8026247B2/en not_active Expired - Fee Related
- 2005-09-14 KR KR1020077005959A patent/KR20070052309A/ko not_active Abandoned
- 2005-09-14 EP EP05850758A patent/EP1794149A2/en not_active Withdrawn
- 2005-09-14 RU RU2010138639/04A patent/RU2448103C2/ru not_active IP Right Cessation
- 2005-09-14 RU RU2007114124/04A patent/RU2416611C2/ru not_active IP Right Cessation
- 2005-09-14 AU AU2005310968A patent/AU2005310968C1/en not_active Ceased
- 2005-09-14 KR KR1020107020440A patent/KR20100111324A/ko not_active Ceased
- 2005-09-14 TW TW094131697A patent/TW200626576A/zh unknown
- 2005-09-14 NZ NZ587805A patent/NZ587805A/en not_active IP Right Cessation
- 2005-09-14 GT GT200500260A patent/GT200500260A/es unknown
- 2005-09-14 MX MX2007003013A patent/MX2007003013A/es active IP Right Grant
-
2007
- 2007-03-05 IL IL181720A patent/IL181720A0/en unknown
- 2007-03-14 EC EC2007007324A patent/ECSP077324A/es unknown
- 2007-03-14 TN TNP2007000093A patent/TNSN07093A1/en unknown
- 2007-03-26 MA MA29778A patent/MA28876B1/fr unknown
- 2007-04-13 NO NO20071875A patent/NO20071875L/no not_active Application Discontinuation
-
2009
- 2009-03-18 AU AU2009201090A patent/AU2009201090B2/en not_active Ceased
- 2009-12-30 RU RU2009149216/04A patent/RU2009149216A/ru unknown
-
2011
- 2011-03-08 JP JP2011050331A patent/JP2011148808A/ja active Pending
- 2011-08-17 US US13/211,765 patent/US20110301157A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008513366A5 (enExample) | ||
| Wissner et al. | 4-Anilino-6, 7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6, 7-dialkoxyquinazoline inhibitors | |
| Renhowe et al. | Design, structure− activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors | |
| HRP20250843T1 (hr) | Inhibitori protein kinaze c i postupci za njihovu upotrebu | |
| CN113365988A (zh) | Shp2抑制剂及其应用 | |
| Hu et al. | Design, synthesis, and biological evaluation of novel quinazoline derivatives as anti‐inflammatory agents against lipopolysaccharide‐induced acute lung injury in rats | |
| CY1119528T1 (el) | Αναστολεις της δραστηριοτητας της κινασης | |
| BG108425A (en) | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor | |
| EA200970280A1 (ru) | Ингибиторы киназ, полезные для лечения пролиферативных заболеваний | |
| EA200970279A1 (ru) | Ингибиторы киназ, полезные для лечения пролиферативных заболеваний | |
| Shi et al. | Discovery of N-(2-phenyl-1H-benzo [d] imidazol-5-yl) quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| JP2013527173A5 (enExample) | ||
| EA200970700A1 (ru) | Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний | |
| NO20073211L (no) | Tibulinbindende anti-cancerstoffer og promedikamenter av disse | |
| ME00937B (me) | Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera | |
| Vasbinder et al. | Discovery and optimization of a novel series of potent mutant B-RafV600E selective kinase inhibitors | |
| JP2011520941A5 (enExample) | ||
| EA021421B1 (ru) | Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы, способ их получения, содержащая их фармацевтическая композиция и способ лечения заболеваний с применением таких соединений | |
| WO2013036232A3 (en) | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases | |
| MY140291A (en) | Sulfoximine-substituted pyrimidines for use as cd and/or vegf inhibitors, the production thereof and their use as drugs | |
| JP2016525076A5 (enExample) | ||
| NZ603654A (en) | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| EA201001030A1 (ru) | Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла | |
| ATE369349T1 (de) | Thiazolderivate und deren verwendung |